Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches
Clinical and Translational Science · 2026-02 · 19 (2)
DOI: 10.1111/cts.70493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 15.02.2026. Verfasst von Zoey Tang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Development, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Project Optimus has been reforming the dose selection and optimization paradigm in oncology. In this context, model‐informed drug development (MIDD) approaches were utilized to validate the optimal dose selection of 6 mg/kg every 3 weeks (Q3W) for datopotamab deruxtecan (Dato‐DXd) in patients with HR‐positive/HER2‐negative breast cancer (HR+/HER2− BC). A Tumor Growth Inhibition (TGI)–Progression‐Free Survival (PFS) modeling framework was developed to assess the relationship between Dato‐DXd PK exposure, tumor dynamics, and PFS, and support virtual trial simulations at different Dato‐DXd dose levels. Simulations suggested that Dato‐DXd at 6 mg/kg Q3W provide superior tumor control and improved PFS compared to a lower dose in patients with HR+/HER2− BC. This work underscores the importance of integrating advanced modeling techniques into the dose optimization paradigm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gaithersburg, Maryland, USA.
- Clinical Development, Oncology R&D, Mississauga, Ontario, Canada.
- Clinical Development, Oncology R&D, Gaithersburg, Maryland, USA.
- Statistics, Oncology R&D, New York, New York, USA.
- Statistics, Oncology R&D, Gaithersburg, Maryland, USA.
- Quantitative Clinical Pharmacology, Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA.
ORCID-Profile: Zoey Tang, KyoungSoo Lim, Manjunatha Munegowda, Sabrina Khan, Diansong Zhou
Zitieren
APA
Tang, Z., Lim, K., Jiang, Y., Dai, D., Munegowda, M., Khan, S., Xu, L., Shi, L., Pan, Y., Hong, Y., Ren, S., Vajjah, P., Gibbs, M., & Zhou, D. (2026). Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches. Clinical and Translational Science, 19(2). https://doi.org/10.1111/cts.70493
Vancouver
Tang Z, Lim K, Jiang Y, Dai D, Munegowda M, Khan S, et al. Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches. Clinical and Translational Science. 2026;19(2). doi:10.1111/cts.70493
BibTeX
@article{Tang2026,
author = {Tang, Zoey and Lim, KyoungSoo and Jiang, Yu and Dai, David and Munegowda, Manjunatha and Khan, Sabrina and Xu, Lu and Shi, Lei and Pan, Yuzhuo and Hong, Ying and Ren, Song and Vajjah, Pavan and Gibbs, Megan and Zhou, Diansong},
title = {Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {2},
doi = {10.1111/cts.70493}
}
EUVIMED